Literature DB >> 8626000

Differing antibody responses to Haemophilus influenzae type b after meningitis or epiglottitis.

P D Johnson1, M Hanlon, D Isaacs, G L Gilbert.   

Abstract

Two common forms of invasive disease due to Haemophilus influenzae type b (Hib) are epiglottitis and meningitis. It is not known why some children develop epiglottitis and others meningitis. To examine the hypothesis that epiglottitis occurs in children who may have been previously exposed to Hib, and who would therefore exhibit a more vigorous antibody response in convalescence, we measured levels of antibody to Hib capsule in 92 children. Geometric mean convalescent-phase IgG, IgA, IgM and total antibody levels were significantly higher in 45 children with epiglottitis than in 47 with meningitis, even after adjustment for age differences (mean total antibody, 95% confidence intervals: meningitis 0.38, 0.34-0.43; epiglottitis: 2.25, 2.0-2.54 micrograms/ml). However, contrary to previous reports, a poor antibody response was only observed in a minority of children with meningitis; the antibody response of the majority was indistinguishable from that observed in children with epiglottitis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8626000      PMCID: PMC2271250          DOI: 10.1017/s095026880005891x

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  28 in total

1.  Haemophilus influenzae type b disease in an Arab Gulf state.

Authors:  V M Novelli; F el-Baba; R G Lewis; P S Bissell
Journal:  Pediatr Infect Dis J       Date:  1989-12       Impact factor: 2.129

2.  Global genetic structure and molecular epidemiology of encapsulated Haemophilus influenzae.

Authors:  J M Musser; J S Kroll; D M Granoff; E R Moxon; B R Brodeur; J Campos; H Dabernat; W Frederiksen; J Hamel; G Hammond
Journal:  Rev Infect Dis       Date:  1990 Jan-Feb

3.  Invasive Haemophilus influenzae type b disease in Alaska: background epidemiology for a vaccine efficacy trial.

Authors:  J I Ward; M K Lum; D B Hall; D R Silimperi; T R Bender
Journal:  J Infect Dis       Date:  1986-01       Impact factor: 5.226

4.  Mechanisms underlying the development of meningitis or epiglottitis in children after Haemophilus influenzae type b bacteremia.

Authors:  L J La Scolea; S V Rosales; R C Welliver; P L Ogra
Journal:  J Infect Dis       Date:  1985-06       Impact factor: 5.226

5.  Outer-membrane protein subtypes of Haemophilus influenzae type b and spread of disease in day-care centers.

Authors:  S J Barenkamp; D M Granoff; R S Munson
Journal:  J Infect Dis       Date:  1981-09       Impact factor: 5.226

6.  Haemophilus influenzae type b infections in Victoria, Australia, 1985 to 1987.

Authors:  G L Gilbert; D A Clements; S J Broughton
Journal:  Pediatr Infect Dis J       Date:  1990-04       Impact factor: 2.129

7.  Haemophilus influenzae type b strains of outer membrane subtypes 1 and 1c cause different types of invasive disease.

Authors:  A K Takala; L van Alphen; J Eskola; J Palmgren; P Bol; P H Mäkelä
Journal:  Lancet       Date:  1987-09-19       Impact factor: 79.321

8.  Correlates of high grade and low grade Haemophilus influenzae bacteremia.

Authors:  G S Marshall; L M Bell
Journal:  Pediatr Infect Dis J       Date:  1988-02       Impact factor: 2.129

9.  Comparison of outer membrane protein subtypes of Haemophilus influenzae type b isolates from healthy children in the general population and from diseased patients.

Authors:  C M Hampton; S J Barenkamp; D M Granoff
Journal:  J Clin Microbiol       Date:  1983-09       Impact factor: 5.948

10.  Haemophilus influenzae type b infection in childhood: history of bacteremia and antigenemia.

Authors:  L J La Scolea; S V Rosales; P L Ogra
Journal:  Infect Immun       Date:  1985-12       Impact factor: 3.441

View more
  1 in total

1.  Immunologic memory in Haemophilus influenzae type b conjugate vaccine failure.

Authors:  J McVernon; P D R Johnson; A J Pollard; M P E Slack; E R Moxon
Journal:  Arch Dis Child       Date:  2003-05       Impact factor: 3.791

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.